Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
White paper on microbial anti-cancer therapy and prevention.
Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G. Forbes NS, et al. Among authors: coffin rs. J Immunother Cancer. 2018 Aug 6;6(1):78. doi: 10.1186/s40425-018-0381-3. J Immunother Cancer. 2018. PMID: 30081947 Free PMC article. Review.
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E, Bergerhoff K, Bozhanova G, Foo S, Patin EC, Whittock H, Buus R, Haider S, Muirhead G, Thway K, Newbold K, Coffin RS, Vile RG, Kim D, McLaughlin M, Melcher AA, Harrington KJ, Pedersen M. Crespo-Rodriguez E, et al. Among authors: coffin rs. J Immunother Cancer. 2020 Aug;8(2):e000698. doi: 10.1136/jitc-2020-000698. J Immunother Cancer. 2020. PMID: 32759235 Free PMC article.
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC. Hu JC, et al. Among authors: coffin rs. Clin Cancer Res. 2006 Nov 15;12(22):6737-47. doi: 10.1158/1078-0432.CCR-06-0759. Clin Cancer Res. 2006. PMID: 17121894 Clinical Trial.
Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.
Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS. Simpson GR, et al. Among authors: coffin rs. Br J Cancer. 2012 Jan 31;106(3):496-507. doi: 10.1038/bjc.2011.577. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240799 Free PMC article.
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.
Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, Newbold KL, Goldsweig H, Coffin R, Nutting CM. Harrington KJ, et al. Clin Cancer Res. 2010 Aug 1;16(15):4005-15. doi: 10.1158/1078-0432.CCR-10-0196. Clin Cancer Res. 2010. PMID: 20670951 Free article. Clinical Trial.
87 results